MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans

• DOI: 10.1126/scitranslmed.aaz7715
• Publication Date: 2020-06-17T23:15:06Z
• Authors: Ilaria Esposito; Paola Cicconi; Anna Morena D’Alise; Anthony Brown; Marialuisa Esposito; Leo Swadling; Peter Johannes Holst; Maria Rosaria Bassi; Mariano Stornaiuolo; Federica Mori; Ventzislav Vassilev; Wenqin Li; Timothy Donnison; Chiara Gentile; Bethany Turner; Annette von Delft; Mariarosaria Del ...; Federica Barra; Alessandra Maria ...; Adele Abbate; Ettore Novellino; Allan Randrup Tho...; Jan Pravsgaard Ch...; Armin Lahm; Fabiana Grazioli; Virginia Ammendola; Loredana Siani; Stefano Colloca; Paul Klenerman; Alfredo Nicosia; Lucy Dorrell; Antonella Folgori; Stefania Capone; Eleanor Barnes; ; Carly Bliss; Emma Ghaffari; Felicity Hartnell; Jakub Kopycinski; Shokouh Makvandi-...; Verity Nevin; Dorota Borys; Dominique Boutriau; Landry Cochard; Lan Lin; Frank Struyf; Tomáš Hanke; Ciaran Bannan; Colim Bergin; Matthias Hoffman; Patrick Schmid; Pietro Vernazza; Clair Gardiner; Elena Woods
• Keywords: CD74

Administration of an MHC class II invariant chain–adjuvanted HCV vaccine in humans leads to enhanced immunogenicity via the proteasome pathway.